Tango Therapeutics (TNGX) Cash from Investing Activities (2020 - 2026)

Tango Therapeutics' Cash from Investing Activities history runs 7 years deep, the most recent figure standing at $9.6 million for Q1 2026.

• On a quarterly basis, Cash from Investing Activities fell 68.51% year-over-year to $9.6 million in Q1 2026; TTM through Mar 2026 was -$61.8 million, a 148.33% decrease from a year earlier, with the FY2025 full-year figure at -$40.9 million, down 147.45% from the prior year.
• Cash from Investing Activities improved to $9.6 million in Q1 2026 per TNGX's latest filing, from -$135.7 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $52.1 million in Q4 2024 and bottomed at -$135.7 million in Q4 2025.
• The 5-year median for Cash from Investing Activities is $16.8 million (2025), against an average of $7.2 million.
• Across the five-year window, Cash from Investing Activities jumped 635.74% in 2022 and sank 472.1% in 2023, its largest moves.
• Year by year, Cash from Investing Activities stood at -$12.6 million in 2022, then soared by 368.56% to $33.9 million in 2023, then surged by 53.79% to $52.1 million in 2024, then sank by 360.69% to -$135.7 million in 2025, then soared by 107.1% to $9.6 million in 2026.
• Per Business Quant, the three latest TNGX Cash from Investing Activities figures stand at $9.6 million (Q1 2026), -$135.7 million (Q4 2025), and $47.5 million (Q3 2025).